[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer]. 1980

G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo

150 patients with lung cancer have been studied from the immunological point of view: the two years that elapsed between the study and processing of the data permitted an evaluation of the prognosis in terms of immunology also. This study has been carried out in vivo by means of skin tests (BCG, PPD, Candida, Varidase, CCB, Mumps, BNCB) and in vitro with lymphocyte blastization in the presence of PHA and dependent antibody cytotoxicity. Serum factors which can interfere with lymphocyte cytotoxicity have also been studied. Peri- and intra-tumour lymphocyte infiltration and the lymph node activation stage have been analyzed in patients who underwent surgery. A real depression of the cell mediated immunity observed in the negative response to skin tests has been found. The study of in vitro parameters showed a deficient blast response in 86% of the cases examined, decreased cytotoxicity in 62% and the presence of inhibiting serum factors in 53%. No correlation was observed between positivity to skin tests, normal response to PHA, normal concentration of inhibiting serum factors on the one hand and survival on the other. The only finding which seems to be correlated with survival is lymphocyte infiltration; its peri- and intrastromal presence on the neoplasia may be associated with a significantly better prognosis.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D004137 Dinitrochlorobenzene A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds. 1-Chloro-2,4-Dinitrobenzene,2,4-Dinitrochlorobenzene,Benzene, 1-Chloro-2,4-Dinitro-,Chlorodinitrobenzene,DNCB,1 Chloro 2,4 Dinitrobenzene,2,4 Dinitrochlorobenzene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D012882 Skin Tests Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity. Skin Test,Test, Skin,Tests, Skin

Related Publications

G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 1989, Sovetskaia meditsina,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 1998, Lung,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
May 2011, Polski przeglad chirurgiczny,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 1998, Anticancer research,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 1992, Indian journal of pediatrics,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 1993, Folia medica,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 2014, Annales de biologie clinique,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
January 1980, Czechoslovak medicine,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
July 1992, Zhonghua yi xue za zhi,
G C Roviaro, and F Varoli, and F Sartori, and F Calabrò, and F Bortolotti, and F Tremolada, and G Fattovich, and A Cecchetto, and P Paruzzolo
June 1977, Minerva chirurgica,
Copied contents to your clipboard!